Bio-Rad Laboratories Inc Class A
BIO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$825.00 | Kxnn | Dhrlgzf |
Bio-Rad Faces Dual Headwinds of Supply Chain and COVID Comps, but No Change to Our Long-Term View
Narrow-moat Bio-Rad faced some headwinds in the first quarter from lower COVID-19 sales and supply chain challenges, though growth declines were not as bad as feared and margin held up well. Our $524 fair value estimate is unchanged.